The Progress of Active Immunotherapy for Parkinson's Disease - PubMed
5 hours ago
- #immunotherapy
- #Parkinson's disease
- #dendritic cell vaccine
- Parkinson's disease (PD) is a neurodegenerative disorder characterized by dopaminergic neuron loss and alpha-synuclein aggregation.
- Current treatments for PD are symptomatic and do not alter disease progression.
- Immune dysregulation and neuroinflammation play a significant role in PD pathology.
- Active immunotherapy is emerging as a potential disease-modifying strategy for PD.
- Immunotherapy platforms include peptide vaccines, genetic vaccines, and dendritic cell (DC) vaccines.
- DC vaccines can enhance protein clearance and restore immune homeostasis.
- Challenges include immune heterogeneity, the blood-brain barrier, and DC vaccine manufacturing variability.
- Future research directions include individualized immunologic profiling and long-acting immunomodulatory formulations.
- Isoform-specific DC powder vaccines targeting alpha-synuclein are under development.
- Active immunotherapy shows promise for modifying PD progression.